BHVNNYSEPharmaceutical PreparationsFiscal year ends December 31
Biohaven Ltd.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$11.35+0.57 (+5.29%)
Close on Oct 19, 2026
- Market cap
- $1.71B
- P/E (TTM)
- –
- Dividend yield
- –
Margins need revenue and profit figures
This company does not report the lines needed to calculate margins.
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|
Returns and balance sheet
7 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2019 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | -759.9% | -310.8% | |
| Return on assets | – | – | -138.5% | |
| Current ratio | – | – | 3.18 | |
| Debt to equity | – | – | 4.59 | |
| Net debt to EBITDA | – | – | -0.01× | |
| Diluted shares | – | 39M | 108M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Biohaven generated $1.97B from operations and spent $14.82M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$1.97B
Used
$14.82M
Capital expenditure$14.82M100%Dividends$00%Share buybacks$00%
DuPont needs revenue, assets and equity
This company does not report all three for consecutive years.
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
2of 7 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$738.82M
- Cash generatingOperating cash flow above zero-$609.44M
- Return on assets improvedROA up on the prior year-164.9% → -120.1%
- Earnings backed by cashOperating cash flow above net income-$609.44M vs -$738.82M
- Less leverageLong-term debt to assets fell0.0% → 52.9%
- Better liquidityCurrent ratio rose3.49 → 3.18
- No dilutionShare count did not rise91M → 108M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose– → –